Morales VEC, Fanghänel G, Sánchez RL, Pavía LA, Díaz BLA

Language: Spanish
References: 40
Page: 472-484
PDF size: 321.32 Kb.

ABSTRACT

From 75 to 80 per cent of the adult people with diabetes die from cardiovascular atherosclerotic disease. In individuals without prior diagnosis of diabetes mellitus, before hospital discharge should be the glycaemic status studied, with measurements of basal glucose levels and HbA1c and when indicated, oral glucose tolerance curve. According to that evaluation a treatment shall be established according to the current guidelines.

REFERENCES

3. Levenson JW, Skerrett PJ, Gaziano JM, Reducing the global burden of cardiovascular disease: The role of risk factors. Prev Cardiol 2002;5:188-199.

4. Cardiovascular Disease: WHO: http://www.who.int/cvd/Cardio- Broch.pdf 2002

5. Velásquez O, Rosas M, Lara A, et al. Prevalencia e interrelación de enfermedades crónicas no trasmisibles y factores de riesgo cardiovascular en México: resultados finales de la ENSA 2000. Arch Cardiol Mex 2003;73:62-77.

6. Fanghänel G, Velásquez-Monroy O, Lara A, Sánchez-Reyes L, et al. Epidemiología cardiovascular en México. Estudio comparativo entre datos Nacional y una población cautiva de Trabajadores en el Distrito Federal. Diabetes Hoy 2004;5:1252-1261.

7. Fanghänel G, Sánchez-Reyes L. Complicaciones macrovasculares en la diabetes tipo 2 y su relación con el riesgo cardiovascular. SAM Diabetes Libro 4. México: Intersistemas, 2008.

8. Goraya T, Leibson C, Palumbo P. Coronary atherosclerosis in diabetes mellitus. A population based autopsy study. J Am Coll Cardiol 2002; 40:946-953.

9. Rosner-Preis S, Hwang Shih-Jen, Coady S, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009;119:1728-1735.

10. Rosner-Preis S, Pencina MJ, Hwang Shih-Jen, et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation 2009;120:212-220.

11. Olaiz G. ENSANUT 2006. Instituto Nacional de Salud Pública. Cuernavaca, México 2006.

12. Morales E. Endocardiocrinología. Síndrome metabólico, diabetes mellitus y cardiopatía isquémica. Análisis integrado de los fundamentos, el diagnóstico y el tratamiento. 1ª ed. Aguascalientes: Rupestre, 2005;p:89-162.

13. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444:860-866.

14. Morales E. Atlas de riesgo cardio metabólico total. De la obesidad hacia la aterotrombosis a través de la metainflamación. Aguascalientes: Atheros, 2009;p:15-50.

15. McGill, McMahan A, Gidding SS. Preventing heart disease in the 21th century. Implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Circulation 2008;117:1216-1227.

16. Berry JD, Liu K, Folsom AR, Lewis CE, Carr JJ, et al. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease. The Coronary Artery Risk Development in Young Adults (CARDIA) study and Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2009;119:382-389.

17. Haffner SM, Lehto S, Ronnemma T. Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.

18. Schramm TK, Gislason GH, Kober L, et al. Diabetic patients requiring glucose-lowering therapy and non diabetics with rior myocardial infarction carry the same cardiovascular risk. A population study of 3.3 million people. Circulation 2008; 117:1945-1954.

19. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.

20. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.

21. Duckworth W, Abraira C, Moritz T, Reda D, Emmanuele N et al for the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139.

22. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591.

23. The BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503-2515.

24. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with sulfonilureas and insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.

25. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complication in overweigth patients with type 2 diabetes (UKPDS-34). Lancet 1998;352:854-865.

26. Canner PL, Berge KG, Wenger NK, et al. Fifteen years mortality in Coronary Drug Proyect patients: long term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255.

27. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trial. Editorial. N Engl J Med 2008;358:2630-2633.

28. Cefalu WT. Glycemic targets and cardiovascular disease. Editorial. N Engl J Med 2008;358:2633-2635.

29. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VADT diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009;119:351-357. Medicina Interna de México Volumen 484 olumen 26, núm. 5, septiembre-octubre 2010 Morales Villegas EC y col.

30. Morales E. Atlas de riesgo cardio metabólico total. De la obesidad hacia la aterotrombosis a través de la metainflamación. 1ª ed. Aguascalientes: Atheros, 2009;p:94-108.

31. Nathan DN, Buse JB, Davidson MB, et al. Consenso de la Asociación Americana de Diabetes (ADA) y de la Asociación Europea para el Estudio de la Diabetes (EASD). Manejo de la hiperglucemia en la diabetes tipo 2: algoritmo de consenso para el comienzo y los ajustes de la terapia. Diabetes Care 2008;31:1-11.

32. www.clinicaltrials.gov/ct/gui/show/NCT00086450 (FREEDOM).

33. Buse JB, Ginsberg HN, Bakris L, et al. Primary prevention of cardiovascular disease in people with diabetes mellitus. A scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115:114-126.

34. BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol 2007;49:1600-1606.

35. Hlatky MA, Boothroyd DB, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 2009;373:1190-1197.

36. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous intervention vs coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009;360:961-972.

37. Boden WE, Taggart DP. Diabetes with coronary disease. A moving target amid evolving therapies? Editorial. N Engl J Med 2009;360:2570-2572.

38. Deedwania P, Kosiborod M, Barret E, et al. Hyperglycemia and Acute Coronary Syndrome. A scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity and Metabolism. Circulation 2008;117:1610-1619.

39. Kushner FG, Hand M, Smith SC, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with SR-elevation myocardial infarction) and a ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update). Circulation 2009;120:2271-2306.

40. Ryan RJ, Cannon CP, Gibler WB. Non ST elevation ACS in the emergency department. Critical pathways in cardiovascular medicine. 2th ed. New York: Lippincott Williams and Wilkins, 2007;p:27-38.